6th Edition of Global Conference on
Addiction Medicine, Behavioral Health and Psychiatry
October 20-22, 2025 | Orlando, Florida, USA
Opioid Agonist Therapy
Opioid Agonist Therapy (OAT) is a widely used treatment for opioid use disorder (OUD), where medications such as methadone or buprenorphine are used to mimic the effects of opioids in a controlled manner. OAT helps reduce withdrawal symptoms and cravings while blocking the euphoric effects of illicit opioid use. By stabilizing brain chemistry, OAT allows individuals to focus on recovery without the constant compulsion to seek out drugs. This approach has been shown to improve long-term outcomes by reducing the risk of overdose, preventing relapse, and enabling individuals to participate more fully in therapeutic interventions. OAT is often combined with counseling, support groups, and other psychosocial treatments to address the behavioral aspects of addiction.
Nile Stanley
University of North Florida, United States
Ann Marie Leonard Zabel
Curry College, United States
Denis Larrivee
University of Navarra, Spain
Scharbach Hugues
Paris University, France
Alphonsus Obayuwana
Triple-H Project LLC, United States
Michelle Charbonnier
MoNetwork, United States
Monica Zuniga Fajuri
Tiburcio Vasquez Health Center, United StatesSubmit your abstract Today
Title : Tailoring biblio-poetry therapies using AI and biofeedback for addiction treatment
Nile Stanley, University of North Florida, United States
Title : Clinical pharmacology of marijuana: Update 2024
Frederick J Goldstein, Philadelphia College of Osteopathic Medicine, United States
Title : Gangstalking is real, should be studied
Sam Vaknin, Southern Federal University, United Kingdom
Title : Decoding aggression, violence, and substance use in adolescents with conduct disorders: Neurochemical pathways and interventions
Ann Marie Leonard Zabel, Curry College, United States
Title : Sensoria driven genetic decoupling and impaired areal integration in diseases of agency
Denis Larrivee, University of Navarra, Spain
Title : Positive outcome of adherence to the reward deficiency syndrome solution system treatment plan: A longitudinal study
Elizabeth Dale Gilley, The Elle Foundation, United States